CompletedPhase 2

Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)

South Korea40 participantsStarted 2010-11

Plain-language summary

The investigators will examine whether 2-cycles of DFP chemotherapy before definitive concurrent chemoradiation therapy (CCRT) can improve progression-free survival in locally advanced (Stage III \& IVM0) hypopharyngeal and base of tongue carcinoma compared to definitive CCRT alone.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Histologically/cytologically proven stage III/IVM0 hypopharyngeal or base of tongue cancer * One or more evaluable or measurable lesion * No prior chemotherapy, radiation, or surgery * ECOG 0-2 Exclusion Criteria: * Distant metastasis * Other malignancy

What they're measuring

To determine whether addition of neoadjuvant chemotherapy before definite CCRT increase progression-free survival(PFS) compared with CCRT only

Timeframe: 18 months after the enrollment of the last patients

Trial details

NCT IDNCT01312350

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-03

View on ClinicalTrials.gov More Hypopharyngeal Cancer trials